Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT06405230 · RECRUITING
Trial details
- NCT number
- NCT06405230
- Sponsor
- GlaxoSmithKline
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-30
- Primary completion
- 2028-08-07
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.